H.R. 7895: PBM Kickback Prohibition Act
H.R. 7895 status: Introduced.
What this bill does
Overall score
Bill summary
AI SummaryThe bill mandates significant changes to compensation structures for pharmacy benefit managers, directly affecting how employer-sponsored drug plans are contracted and audited under ERISA.
Key analysis
Impact analysis
Environment
Benefits
- No direct impact on environmental policy.
Risks
- No direct impact on environmental policy.
Economy
Benefits
- Reduces hidden conflicts of interest in drug plan contracting.
- Promotes market competition by eliminating pay-to-play schemes.
Risks
- May increase compliance and documentation costs for brokers.
- Potential for litigation regarding the definition of fair market value.
Society
Benefits
- Could lower drug costs for employees through more transparent plan management.
- Improves alignment of incentives between consultants and plan sponsors.
Risks
- Implementation transition may cause brief administrative disruption in health plans.
How trustworthy & consequential it is
Confidence
highhigh
Information is complete and verified.
Analysis status
Full bill text (Congress.gov)
Source used for this bill's analysis.
The 'fair market value' documentation requirement may result in increased legal disputes over broker compensation.
Applies specifically to ERISA-covered private sector plans.
Where it stands
Introduced
CurrentIntroduced
Committee
UpcomingFloor
UpcomingEnacted
UpcomingHow it affects your district
Set your location
Add your district to see how this bill may affect your community and who to contact.
Take action
Contact your representatives
Let them know how you feel about this bill.
Share your view
Join the discussion and see what others are saying.
Track this bill
Stay updated on progress and changes.